Cargando…

Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL

SIMPLE SUMMARY: The emergence of resistant cells remains a major obstacle for chemotherapy treatment of metastatic colorectal cancers. Improvement of the therapeutic response requires a thorough understanding of the mechanisms of resistance as well as informative biomarkers. In the REVEAL study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumbrink, Jörg, Bohlmann, Lisa, Mamlouk, Soulafa, Redmer, Torben, Peilstöcker, Daniela, Li, Pan, Lorenzen, Sylvie, Algül, Hana, Kasper, Stefan, Hempel, Dirk, Kaiser, Florian, Michl, Marlies, Bartsch, Harald, Neumann, Jens, Klauschen, Frederick, von Bergwelt-Baildon, Michael, Modest, Dominik Paul, Stahler, Arndt, Stintzing, Sebastian, Jung, Andreas, Kirchner, Thomas, Schäfer, Reinhold, Heinemann, Volker, Holch, Julian W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367450/ https://www.ncbi.nlm.nih.gov/pubmed/35892888 http://dx.doi.org/10.3390/cancers14153631

Ejemplares similares

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
por: Torlot, Lucien, et al.
Publicado: (2022)

Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials
por: Stahler, Arndt, et al.
Publicado: (2020)

Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy
por: von Baumgarten, Louisa, et al.
Publicado: (2020)

Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer
por: Michl, M., et al.
Publicado: (2020)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab
por: Froelich, Matthias F., et al.
Publicado: (2018)

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
por: Ohnmacht, Alexander J., et al.
Publicado: (2023)

p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy
por: Kumbrink, Jörg, et al.
Publicado: (2021)

Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) Molecular Tumor Board
por: Heinrich, Kathrin, et al.
Publicado: (2022)

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial
por: von Einem, Jobst C., et al.
Publicado: (2017)

Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
por: Weiss, L., et al.
Publicado: (2023)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Robust in-silico identification of Cancer Cell Lines based on RNA and targeted DNA sequencing data
por: Otto, Raik, et al.
Publicado: (2019)

EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3)
por: Pretzsch, Elise, et al.
Publicado: (2022)

Expression of CIB1 correlates with colorectal liver metastases but not with peritoneal carcinomatosis
por: Jacob, Sven, et al.
Publicado: (2021)

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV
por: Fey, Theres, et al.
Publicado: (2022)

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
por: Modest, Dominik Paul, et al.
Publicado: (2020)

FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer
por: Raschzok, Nathanael, et al.
Publicado: (2022)

Implementing precision oncology for sarcoma patients: the CCC(LMU)molecular tumor board experience
por: Berclaz, Luc M., et al.
Publicado: (2023)

Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer
por: Boos, Sophie L., et al.
Publicado: (2021)

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich(LMU) Molecular Tumor Board
por: Dorman, Klara, et al.
Publicado: (2023)

DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer
por: Mamlouk, Soulafa, et al.
Publicado: (2017)

Ten things the hematologist wants you to know about CAR-T cells
por: Böll, Boris, et al.
Publicado: (2020)

Severe hypertension and (renal) thrombotic microangiopathy: solving the puzzle
por: Wehrmann, Florian, et al.
Publicado: (2023)

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
por: Fischer, Laura E., et al.
Publicado: (2022)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial
por: Giessen, C, et al.
Publicado: (2013)

Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers
por: Fischer, Laura E., et al.
Publicado: (2022)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial
por: Kurreck, Annika, et al.
Publicado: (2022)

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
por: Modest, Dominik Paul, et al.
Publicado: (2017)

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
por: Hofmann, Felix O., et al.
Publicado: (2022)

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
por: Heinrich, K., et al.
Publicado: (2023)

HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research
por: Hofheinz, Ralf, et al.
Publicado: (2023)

Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer
por: Jaitner, Stefanie, et al.
Publicado: (2022)

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
por: Guenther, Michael, et al.
Publicado: (2023)

Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe
por: Gastl, Bastian, et al.
Publicado: (2020)

A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich
por: Zhang, Danmei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_69uh3bcj84kn0q8aigvcq613g9